A model of healing of Los Angeles grades C and D reflux oesophagitis: Is there an optimal time of acid suppression for maximal healing?

Alimentary Pharmacology and Therapeutics

Volumn 32, Issue 3, 2010, Pages 443-447

  Katz, P O ^a   Johnson, D A ^b   Levine, D ^c   Rohss K ^d   Junghard, O ^d   Astrand M ^d   Nagy, P ^d  

^a ALBERT EINSTEIN MEDICAL CENTER   (United States)

^b EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^c ASTRAZENECA   (United Kingdom)

^d ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ATTAPULGITE; ESOMEPRAZOLE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; FEMALE; GASTRIC PH MONITORING; GASTROSCOPY; HEALING; HELICOBACTER INFECTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REFLUX ESOPHAGITIS; STOMACH ACID; STOMACH PH;

ADULT; AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ESOPHAGEAL PH MONITORING; ESOPHAGITIS, PEPTIC; FEMALE; HUMANS; HYDROGEN-ION CONCENTRATION; LOS ANGELES; MALE; MIDDLE AGED; OMEPRAZOLE; WOUND HEALING; YOUNG ADULT;

EID: 77954331465     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2010.04367.x     Document Type: Article

References (26)

1. Johnsson F, Joelsson B, Gudmundsson K, Greiff L. Symptoms and endoscopic findings in the diagnosis of gastroesophageal reflux disease. Scand J Gastroenterol 1987 22:714 718. (Pubitemid 17134657)
2. Voutilainen M, Sipponen P, Mecklin JP, Juhola M, Farkkila M. Gastroesophageal reflux disease: prevalence, clinical, endoscopic and histopathological findings in 1,128 consecutive patients referred for endoscopy due to dyspeptic and reflux symptoms. Digestion 2000 61:6 13.
3. Dent J. Roles of gastric acid and pH in the pathogenesis of gastro-oesophageal reflux disease. Scand J Gastroenterol Suppl 1994 201:55 61. (Pubitemid 24165477)
4. Armstrong D. Review article: gastric pH - the most relevant predictor of benefit in reflux disease? Aliment Pharmacol Ther 2004 20 (Suppl. 5 19 26.
5. Hunt RH. The relationship between the control of pH and healing and symptom relief in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1995 9 (Suppl. 1 3 7.
6. Hunt RH. Importance of pH control in the management of GERD. Arch Intern Med 1999 159:649 657.
7. Kahrilas PJ, Shaheen NJ, Vaezi MF. American Gastroenterological Association Institute technical review on the management of gastroesophageal reflux disease. Gastroenterology 2008 135:1392 1413.
8. Lundell LR, Dent J, Bennett JR, et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut 1999 45:172 180.
9. Katz PO, Ginsberg GG, Hoyle PE, Sostek MB, Monyak JT, Silberg DG. Relationship between intragastric acid control and healing status in the treatment of moderate to severe erosive oesophagitis. Aliment Pharmacol Ther 2007 25:617 628.
10. Bell NJ, Burget D, Howden CW, Wilkinson J, Hunt RH. Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion 1992 51 (Suppl. 1 59 67.
11. Kahrilas PJ, Dent J, Lauritsen K, et al. A randomized, comparative study of three doses of AZD0865 and esomeprazole for healing of reflux esophagitis. Clin Gastroenterol Hepatol 2007 5:1385 1391.
12. Dent J, Kahrilas PJ, Hatlebakk J, et al. A randomized, comparative trial of a potassium-competitive acid blocker (AZD0865) and esomeprazole for the treatment of patients with nonerosive reflux disease. Am J Gastroenterol 2008 103:20 6.
13. Sharma P, Shaheen NJ, Perez MC, et al. Clinical trials: healing of erosive oesophagitis with dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed-release formulation - results from two randomized controlled studies. Aliment Pharmacol Ther 2009 29:731 741.
14. Orlando RC. Esophageal damage and repair in GERD. J Clin Gastroenterol 2007 41:S108 13.
15. Tack J, Koek G, Demedts I, Sifrim D, Janssens J. Gastroesophageal reflux disease poorly responsive to single-dose proton pump inhibitors in patients without Barrett's esophagus: acid reflux, bile reflux, or both? Am J Gastroenterol 2004 99:981 988.
16. Röhss K, Hasselgren G, Hedenström H. Effect of esomeprazole 40 mg vs omeprazole 40 mg on 24-hour intragastric pH in patients with symptoms of gastroesophageal reflux disease. Dig Dis Sci 2002 47:954 958.
17. Miner P Jr., Katz PO, Chen Y, Sostek M. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol 2003 98:2616 2620.
18. Röhss K, Lind T, Wilder-Smith C. Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms. Eur J Clin Pharmacol 2004 60:531 539. (Pubitemid 39517904)
19. Miner P Jr., Katz PO, Chen Y, Sostek M. Reanalysis of intragastric pH results based on updated correction factors for Slimline and Zinetics 24 single-use pH catheters. Am J Gastroenterol 2006 101:404 405.
20. Kahrilas PJ, Falk GW, Johnson DA, et al. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. The Esomeprazole Study Investigators. Aliment Pharmacol Ther 2000 14:1249 1258.
21. Richter JE, Kahrilas PJ, Johanson J, et al. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol 2001 96:656 665.
22. Castell DO, Kahrilas PJ, Richter JE, et al. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol 2002 97:575 583.
23. Fennerty MB, Johanson JF, Hwang C, Sostek M. Efficacy of esomeprazole 40 mg vs. lansoprazole 30 mg for healing moderate to severe erosive oesophagitis. Aliment Pharmacol Ther 2005 21:455 463.
24. Labenz J, Armstrong D, Lauritsen K, et al. A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis: the EXPO study. Aliment Pharmacol Ther 2005 21:739 746.
25. Schmitt C, Lightdale CJ, Hwang C, Hamelin B. A multicenter, randomized, double-blind, 8-week comparative trial of standard doses of esomeprazole (40 mg) and omeprazole (20 mg) for the treatment of erosive esophagitis. Dig Dis Sci 2006 51:844 850. (Pubitemid 44030800)
26. Koek GH, Sifrim D, Lerut T, Janssens J, Tack J. Multivariate analysis of the association of acid and duodeno-gastro-oesophageal reflux exposure with the presence of oesophagitis, the severity of oesophagitis and Barrett's oesophagus. Gut 2008 57:1056 1064.